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Objectives: Talimogene laherparepvec is the first oncolytic immunotherapy to receive 
approval in Europe, the USA and Australia. In the randomized, open-label Phase III OPTiM 
trial (NCT00769704), talimogene laherparepvec significantly improved durable response rate 
(DRR) versus granulocyte-macrophage colony-stimulating factor (GM-CSF) in 436 patients 
with unresectable stage IIIB–IVM1c melanoma. The median overall survival (OS) was longer 
versus GM-CSF in patients with earlier-stage melanoma (IIIB–IVM1a). Here, we report a 
detailed subgroup analysis of the OPTiM study in patients with IIIB–IVM1a disease.
Patients and methods: The patients were randomized (2:1 ratio) to intralesional talimogene 
laherparepvec or subcutaneous GM-CSF and were evaluated for DRR, overall response rate 
(ORR), OS, safety, benefit–risk and numbers needed to treat. Descriptive statistics were used 
for subgroup comparisons.
Results: Among 249 evaluated patients with stage IIIB–IVM1a melanoma, DRR was higher 
with talimogene laherparepvec compared with GM-CSF (25.2% versus 1.2%; P,0.0001). ORR 
was also higher in the talimogene laherparepvec arm (40.5% versus 2.3%; P,0.0001), and 27 
patients in the talimogene laherparepvec arm had a complete response, compared with none in 
GM-CSF-treated patients. The incidence rates of exposure-adjusted adverse events (AE) and 
serious AEs were similar with both treatments.
Conclusion: The subgroup of patients with stage IIIB, IIIC and IVM1a melanoma (57.1% of 
the OPTiM intent-to-treat population) derived greater benefit in DRR and ORR from talimogene 
laherparepvec compared with GM-CSF. Talimogene laherparepvec was well tolerated.
Keywords: benefit–risk, clinical trial, durable response rate, immunotherapy, oncolytic virus, 
talimogene laherparepvec
Introduction
Oncolytic viruses, with natural or engineered effects on the immune system, are novel 
anti-cancer therapies.1 These oncolytic immunotherapies are designed to replicate in and 
kill tumor cells without harming normal tissues and increase host immune cell recognition 
of tumor and viral antigens exposed during oncolysis.2 Talimogene laherparepvec is the 
first oncolytic immunotherapy to show an improved response in a Phase III randomized 
clinical trial and recently became the first oncolytic immunotherapy to be approved by 
the European Commission following approval of the product by the US Food and Drug 
correspondence: Kevin J harrington
The institute of cancer research/
The royal Marsden hospital nihr 
Biomedical research centre, 
london sW3 6JB, UK
Tel +44 20 7153 5157
Fax +44 20 7808 2235
email kevin.harrington@icr.ac.uk 
Journal name: OncoTargets and Therapy
Article Designation: Original Research
Year: 2016
Volume: 9
Running head verso: Harrington et al
Running head recto: Talimogene laherparepvec versus GM-CSF in stage IIIB–IVM1a melanoma
DOI: http://dx.doi.org/10.2147/OTT.S115245
 
O
nc
oT
ar
ge
ts
 a
nd
 T
he
ra
py
 d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
19
3.
62
.2
18
.7
9 
on
 1
3-
De
c-
20
16
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
OncoTargets and Therapy 2016:9submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
7082
harrington et al
Administration (FDA).3–6 Talimogene laherparepvec is a her-
pes simplex virus (HSV) type 1 (HSV-1)-based intralesional 
oncolytic immunotherapy, modified to attenuate viral pathoge-
nicity, increase antigen presentation and induce selective tumor 
lysis.7–9 An enhanced anti-tumor immune response is achieved 
though the insertion and expression of the gene encoding 
human granulocyte-macrophage colony-stimulating factor 
(GM-CSF), which results in local GM-CSF production and the 
subsequent induction of tumor-specific T-cell responses.7–9
The FDA approval for talimogene laherparepvec was 
based on the overall, intent-to-treat (ITT) population of 
the randomized, multicenter, open-label Phase III OPTiM 
study (NCT00769704), which included 436 patients with 
unresectable stage IIIB–IVM1c melanoma. In this ITT 
population, intralesional talimogene laherparepvec significantly 
improved durable response rate (DRR; a continuous response 
for $6 months, primary endpoint) compared with subcutaneous 
GM-CSF (16.3% versus 2.1%, respectively; P,0.001) and was 
well tolerated.6 Secondary endpoint analyses included overall 
survival (OS), and a median survival difference of 23.3 versus 
18.9 months was observed with talimogene laherparepvec 
versus GM-CSF (hazard ratio [HR]: 0.79; 95% confidence 
interval [CI]: 0.62, 1.00; P=0.051).6 Further analysis showed 
talimogene laherparepvec efficacy to be greater in patients 
with unresectable melanoma that was regionally or distantly 
metastatic with no visceral disease.6 In patients with stage IIIB–
IVM1a melanoma, median OS was longer in the talimogene 
laherparepvec arm (41.1 months; 95% CI: 30.6 months, not 
evaluable) compared with the GM-CSF arm (21.5 months; 
95% CI: 17.4, 29.6 months). The HR for the difference between 
the arms was 0.57 (95% CI: 0.40, 0.80; P,0.001 [descrip-
tive]). Based on these results, as well as the DRR findings 
reported herein, talimogene laherparepvec was approved in 
Europe for adults with unresectable stage IIIB, IIIC or IVM1a 
melanoma with no bone, brain, lung or other visceral disease.4 
Consequently, we report here a detailed analysis of the efficacy 
and safety of talimogene laherparepvec in patients with stage 
IIIB/C or IVM1a melanoma in the OPTiM study (reflecting the 
European Union indication), including analysis of benefit–risk 
and the numbers needed to treat for either benefit or harm.
Patients and methods
Patients
The full inclusion/exclusion criteria of the OPTiM study have 
been described in detail previously6 and are reported briefly here. 
Eligible patients were $18 years of age, with histologically/
cytologically confirmed, unresectable, bidimensionally mea-
surable stage IIIB–IV melanoma, which was suitable for direct 
or ultrasound-guided injection. Eastern Cooperative Oncology 
Group (ECOG) performance status (PS) #1, adequate organ 
function and serum lactate dehydrogenase #1.5× upper limit of 
normal were also required. Patients with bone metastases, $3 
visceral metastases (except lung or nodal metastases associ-
ated with visceral organs), any visceral metastasis .3 cm, or 
active cerebral metastases were excluded; liver metastases had 
to be stable for $1 month before random assignment. Patients 
in need of intermittent or chronic treatment with an antiviral 
agent (for example, acyclovir) or high-dose steroids were also 
excluded. Both first-line and previously treated patients were 
enrolled in the OPTiM study.
The patients provided written informed consent, and 
the protocol and study procedures received approval from 
all participating study centers (Table S1). Amgen Inc, the 
sponsor of the study, was responsible for the development 
of the protocol. The trial is registered on ClinicalTrials.gov 
(identifier: NCT00769704).
study design and treatment
OPTiM was an open-label, Phase III clinical trial conducted 
at 64 centers in Canada, South Africa, the United Kingdom 
and the United States. Patients were randomized 2:1 to receive 
intralesional talimogene laherparepvec or subcutaneous recom-
binant GM-CSF. Random assignment was stratified by site 
of first recurrence, presence of liver metastases, disease stage 
and prior nonadjuvant systemic treatment. Talimogene laher-
parepvec was administered by intralesional injection at an initial 
concentration of 106 pfu/mL on Day 1, followed by a concen-
tration of 108 pfu/mL on Day 22 (cycle 1) and then once every 
2 weeks in 28-day cycles for 12 months or up to 18 months 
in patients with stable or responding disease at 12 months. 
Discontinuation of treatment due to progressive disease per 
response assessment criteria was not required before 24 weeks, 
unless alternate therapy was clinically indicated or the patient 
was intolerant to treatment. Injected volume per lesion ranged 
from 0.1 mL for lesions ,0.5 cm to 4.0 mL for lesions .5 cm 
in the longest diameter (Table 1). GM-CSF 125 µg/m2 was 
administered subcutaneously once daily for 14 days in 28-day 
cycles for 12 months or up to 18 months in patients with stable 
or responding disease at 12 months. Further details related to 
dosing in this study have been reported previously.6
Table 1 Talimogene laherparepvec injection volume by lesion size
Lesion size (longest diameter) T-VEC injection volume
.5 cm Up to 4 ml
.2.5–5 cm Up to 2 ml
.1.5–2.5 cm Up to 1 ml
.0.5–1.5 cm Up to 0.5 ml
#0.5 cm Up to 0.1 ml
Abbreviation: T-Vec, talimogene laherparepvec.
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endpoints and assessments
We report exploratory analyses for the subgroup of patients 
with stage IIIB/IIIC or IVM1a melanoma. The primary end-
point of OPTiM was DRR, defined as the rate of objective 
response (complete response [CR] or partial response [PR]) 
lasting $6 months continuously and with onset beginning 
within the first 12 months. Additional efficacy assessments 
included overall response rate (ORR), OS (time from ran-
domization to death), time to treatment failure (TTF), dura-
tion of response, incidence and time to the use of subsequent 
anti-cancer treatment (defined as the time from randomization 
to the first dose) and health-related quality of life (HRQoL). 
Furthermore, a number needed to treat to achieve a benefit 
(NNTB) analysis and a number needed to treat to experience 
a harm (NNTH) analysis were performed.10,11
For the purposes of evaluating response, visible or pal-
pable lesions were clinically assessed with a caliper or ruler 
every 4 weeks. Whole-body computed tomography (CT), 
positron emission tomography (PET) or PET–CT was used to 
assess deeper palpable lesions and nonpalpable subcutaneous 
and distant metastatic lesions every 3 months. Response was 
evaluated per modified World Health Organization criteria.12 
Patients with a best response per investigator of CR or PR 
or receiving treatment for $9 months were evaluated by a 
blinded endpoint assessment committee (EAC).
The Functional Assessment of Cancer Therapy-Biologic 
Response Modifier (FACT-BRM) questionnaire was used to 
assess improvements in HRQoL.13 The trial outcome index 
(TOI; sum of scores for physical well-being, functional 
well-being and two treatment-specific subscales: additional 
concerns [physical] and additional concerns [mental]), 
FACT-BRM total score and the total score in each of the six 
FACT-BRM subdomains as well as in three individual items 
(overall HRQoL, pain and ability to work) were assessed. 
Patients were required to complete the questionnaire on Day 1 
of each treatment cycle (before any treatment-related study 
procedures, including administration of investigational prod-
uct) and at the final (end of treatment) visit. Improvement was 
defined as an increase from baseline sustained for $1 cycle. 
Clinically relevant improvements in TOI and FACT-BRM 
total score were defined as increases of $5 points, improve-
ments in individual domains were defined as increases 
of $2 points and improvements in individual items were 
defined as increases of $1 point.14 Patients with baseline 
scores that allowed for the required absolute improvement and 
who had at least one post-baseline score were evaluable.
For the NNTB analysis, the benefits included DRR, ORR, 
probability of being alive, probability of treatment failure 
and probability of no new therapy. For the NNTH analysis, 
harms (risks) were defined based on the mechanism of action 
of talimogene laherparepvec and included immune-mediated 
events, oral herpes and bacterial cellulitis. Confirmation of 
bacterial cellulitis or cause of herpes (HSV or talimogene 
laherparepvec) was not required. A fixed follow-up period 
of 18 months was selected for the analysis (the maximum 
duration of treatment in the study). The incidence, severity 
and type of adverse events (AEs) occurring between the 
first administration of study treatment and 30 days after 
last treatment were evaluated using the National Cancer 
Institute Common Terminology Criteria for Adverse Events 
(version 3.0).
statistical analysis
Sample size calculations for the OPTiM study have been 
reported elsewhere.6
In this subgroup analysis, efficacy was evaluated in all 
patients with stage IIIB/IIIC or IVM1a melanoma from 
the ITT population (not all treated). The safety analysis 
included patients with stage IIIB/IIIC or IVM1a melanoma 
who received at least one dose of talimogene laherparepvec 
or GM-CSF.
Disease stage was prespecified as a randomization 
stratification factor in the OPTiM study design and for sub-
group analysis in the statistical analysis plan. All subgroup 
comparisons are descriptive with statistical significance 
assessed at a nominal two-sided 5% level without multiplicity 
adjustment. An unadjusted Fisher’s exact test was used to 
evaluate the difference in DRR and ORR between treatment 
arms. Unadjusted log-rank tests and Cox proportional hazards 
models were used to evaluate OS, TTF, time to response and 
duration of response. All analyses were performed using SAS 
software (version 9.2; SAS Institute Inc., Cary, NC, USA).
An analysis was performed to examine the relationship 
between durable response and OS. In a landmark analysis, 
OS was compared for patients who had achieved a durable 
response and were alive at 12 months after randomization with 
those who had not achieved a durable response and were alive 
at 12 months, mitigating the potential for lead-time bias.15 
Patients who died or who were censored before the landmark 
time were not included in this analysis. The association 
between durable response and the time to the use of subse-
quent systemic anti-melanoma treatment was also evaluated 
in a landmark analysis. These analyses were performed using 
a Cox proportional hazards model and log-rank test.
NNTB and NNTH were calculated as the reciprocal of 
the difference in the proportion of patients with the specified 
benefit or risk between the active treatment (talimogene laher-
parepvec) and the control group (GM-CSF) by 18 months.
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NNTB
Benefit proportion (
Benefit
talimogene laherparepvec
=
−
1
)
proportion (GM-CSF)
NNTH
Risk proportion (
Risk propo
talimogene laherparepvec
=
−
1
)
rtion (GM-CSF)
Results
Patient characteristics, disposition 
and treatment
In total, 249 patients with stage IIIB (n=34), IIIC (n=97), or 
IVM1a (n=118) disease (57.1% of the OPTiM ITT population) 
were randomized to receive talimogene laherparepvec (n=163) 
or GM-CSF (n=86). Patient disposition is shown in Figure 1. 
Baseline demographic and clinical characteristics for these 
patients are shown in Table 2. Overall, baseline characteris-
tics were generally balanced between the talimogene laher-
parepvec and GM-CSF arms. More patients in the talimogene 
laherparepvec versus the GM-CSF arm had an ECOG PS of 0 
(73.6% versus 62.8%, respectively). Details relating to sites of 
disease are captured in Table 2. Additionally, baseline HSV-1 
seropositive status was higher in the talimogene laherparepvec 
arm (62.0% versus 54.7%). BRAF status was known in 32% 
of patients and was equally distributed between the two treat-
ment groups. More than half (55.0%) of the patients had not 
received prior therapy at baseline.
The median duration of treatment in the talimogene laher-
parepvec and GM-CSF groups was 25.7 (range 3.6–78.9) and 
?????????????????????????????????????????????????
???????????????????????????????????????????????????????????????????? ???????
????????????????????????????????????????? ??????????? ????????????????????????????? ??????????????????????????????????????????????? ????????????????????????? ???????? ??????????? ?????????????????????? ??????????????????????? ?????
?????????????????
????????????????????????????????????????? ?????????????????
???????????
??????????????????????????????????????????????????????
?????????????????????????????????????????? ???????
?????
????????????????????????????????????
????????????????????????????????????????????????????????????????????? ??????
????????????????????????????????????????? ?????????? ????????????????????????????? ?????????????????????????????????????????????? ???????????????????????? ???????? ??????????? ?????????????????????? ??????????????????????? ?????
?????????????????
????????????????????????????????????????? ?????????????????
???????????
??????????????????????????????????????????????????????
?????????????????????????????????????????? ??????
??????
????????????????????????????????????
Figure 1 Patient disposition for the stage iiiB/c, iVM1a OPTiM subpopulation.
Notes: aTalimogene laherparepvec was administered intralesionally #4 ml ×106 pfu/ml once and, after 3 weeks, $4 ml ×108 pfu/ml every 2 weeks. bgM-csF was 
administered 125 µg/m2 subcutaneously for 14 days in 4-week cycles.
Abbreviations: AE, adverse event; CI, confidence interval; CR, complete response; GM-CSF, granulocyte-macrophage colony-stimulating factor; NNTB, number needed to 
treat to achieve a benefit; NNTH, number needed to treat to experience a harm; PR, partial response; T-VEC, talimogene laherparepvec.
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10.0 weeks (range 0.6–58.3), respectively. The patients in 
the talimogene laherparepvec arm received a median of 14 
injections (range 2–38).
Durable and overall response
DRR per EAC assessment was higher in patients treated 
with talimogene laherparepvec compared with the GM-CSF 
group in the stage IIIB/C or IVM1a subpopulation (25.2% 
versus 1.2%, respectively; treatment difference 24% [95% 
CI: 17.0–31.0]; P,0.0001; Table 3). The onset of durable 
response prior to 12 months in either treatment arm was asso-
ciated with a 94% decrease in the risk of death (HR 0.06; [95% 
CI: 0.01, 0.45]; P=0.0002). Similarly, regardless of treatment 
arm, the onset of durable response prior to 9 or 18 months was 
associated with a 90% or 85% decrease in the risk of death, 
respectively. Among the 41 patients with a durable response 
to talimogene laherparepvec, 20 (49%) experienced progres-
sion prior to response (defined as the appearance of a new 
lesion or .25% increase in total baseline tumor area).
ORR was also higher in the talimogene laherparepvec 
arm (40.5% versus 2.3%, respectively; P,0.0001). In total, 
27 patients (16.6%) in the talimogene laherparepvec arm had 
a CR compared with no GM-CSF-treated patients (0.0%; 
Table 3). The estimated 5-year survival rate for patients with 
an overall response was 78%.
Among responding patients in the talimogene laher-
parepvec arm (n=66), the median time to response was 
4.0 months (95% CI: 3.2, 5.0) compared with 3.8 months 
(95% CI: 1.9, 5.6) for the two responding patients in the 
GM-CSF group. The median duration of response was 
not reached in the talimogene laherparepvec responders; 
Table 2 Baseline demographic and clinical characteristics for the 
stage iiiB/c or iVM1a OPTiM subpopulation
T-VEC 
(n=163)
GM-CSF 
(n=86)
age, years
Median (range) 63 (24–94) 63 (28–91)
sex, n (%)
Male 92 (56.4) 47 (54.7)
Female 71 (43.6) 39 (45.3)
Disease stage, n (%)
iiiB 22 (13.5) 12 (14.0)
iiic 66 (40.5) 31 (36.0)
iVM1a 75 (46.0) 43 (50.0)
ecOg Ps, n (%)
0 120 (73.6) 54 (62.8)
1 42 (25.8) 24 (27.9)
Missing 1 (0.6) 8 (9.3)
sites of disease,a n (%)
skin 110 (67.5) 49 (57.0)
lymph nodes 70 (42.9) 32 (37.2)
soft tissue 79 (48.5) 35 (40.7)
lung 0 (0.0) 0 (0.0)
liver 0 (0.0) 0 (0.0)
Brain 0 (0.0) 0 (0.0)
Other metastases 4 (2.5)b 0 (0.0)
Other 19 (11.7) 15 (17.4)
Missing 1 (0.6) 8 (9.3)
lactate dehydrogenase, n (%)
#Uln 154 (94.5) 75 (87.2)
.Uln 2 (1.2) 2 (2.3)
Unknown 1 (0.6) 1 (1.2)
hsV-1 serostatus, n (%)
negative 51 (31.3) 25 (29.1)
Positive 101 (62.0) 47 (54.7)
Unknown 11 (6.7) 14 (16.3)
BRAF status, n (%)
Mutated 27 (16.6) 14 (16.3)
Wild type 24 (14.7) 14 (16.3)
Unknown or missing 112 (68.7) 58 (67.4)
line of therapy, n (%)
First 92 (56.4) 45 (52.3)
second or later 71 (43.6) 41 (47.7)
T-VEC 
(n=71)
GM-CSF 
(n=41)
Previous therapy, n (%)c
chemotherapy 28 (39.4) 14 (34.1)
Biological/targeted therapy (investigational)d 11 (15.5) 7 (17.1)
Vemurafenib 1 (1.4) 0 (0.0)
immunotherapy 36 (50.7) 22 (53.7)
interleukin-2 13 (18.3) 9 (22.0)
interferon alpha 24 (33.8) 18 (43.9)
gM-csF 0 (0.0) 0 (0.0)
anti-cTla4 3 (4.2) 2 (4.9)
anti-PD1 0 (0.0) 0 (0.0)
(Continued)
Table 2 (Continued)
T-VEC 
(n=71)
GM-CSF 
(n=41)
isolated limb perfusion or infusion 17 (23.9) 8 (19.5)
radiotherapy 19 (26.8) 9 (22.0)
Other 11 (15.5) 5 (12.2)
Notes: alymph nodes: axillary lymph nodes, cervical lymph nodes, thoracic lymph 
nodes, intra-abdominal lymph nodes and inguinal lymph nodes. Other metastases: 
locally advanced disease involving a visceral organ or impacting other non-skin and 
non-lymphatic organs, including thyroid gland, heart/pericardium, gastrointestinal 
tract, pancreas, gallbladder, kidney, uterus, ovary, adrenal gland and peritoneum. 
soft tissues: soft tissue of arm, leg and trunk/back. Others: pleural effusion, ascites 
and others (the locations already included as “other metastases” were excluded). 
bMetastases in these patients were reported in the case report form at baseline and 
may have appeared at additional sites after this point. csubset of patients reported to 
have $1 line of prior therapy (patients could be treated by multiple agents belonging 
to different categories). dBiological therapy included sorafenib, bevacizumab, 
tamoxifen, thalidomide and others.
Abbreviations: ecOg, eastern cooperative Oncology group; gM-csF, granulocyte-
macrophage colony-stimulating factor; hsV-1, herpes simplex virus type 1; Ps, 
performance status; T-Vec, talimogene laherparepvec; Uln, upper limit of normal.
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46 patients (69.7%) were still in response at the last tumor 
assessment for the primary analysis. The estimated prob-
ability of being in response at 15 months from the response 
onset was 64% (95% CI: 49%, 75%) among talimogene 
laherparepvec responders.
Time to treatment failure
The median TTF was 13.1 months (95% CI: 8.3 months to not esti-
mable) in the talimogene laherparepvec arm versus 3.3 months 
(95% CI: 2.8–4.3 months) in the GM-CSF arm (HR 0.27; 
95% CI: 0.19, 0.39; Table 3).
Overall survival
The median OS and Kaplan–Meier survival plot for the stage 
IIIB/C or IVM1a subpopulation have been published previ-
ously.6 At the time of the primary OS analysis, 137 patients 
had died in this subpopulation, including 80 (49.1%) receiv-
ing talimogene laherparepvec and 57 (66.3%) of those in the 
GM-CSF arm (median OS 41.1 versus 21.5 months). The 
estimated 12-, 24-, 36- and 48-month survival rates were all 
higher in the talimogene laherparepvec group compared with 
the GM-CSF group (Table 3).
incidence of selected systemic anti-
cancer treatment and time to first use
Following talimogene laherparepvec/GM-CSF therapy, 
systemic anti-cancer treatment (including ipilimumab, 
vemurafenib, dabrafenib, trametinib or a PD1 antibody) was 
used in 41.1% of talimogene laherparepvec-treated patients 
compared with 50.0% of patients who received GM-CSF 
(Table 3). Subsequent anti-cancer therapy was given at 
a median of 9.7 and 8.8 months after randomization to 
talimogene laherparepvec and GM-CSF treatment, respec-
tively (Table 3). Among patients with tumor assessments 
for $9 months, durable response in either treatment arm 
was associated with a 67% reduction in the risk of initiating 
subsequent therapy (HR 0.33; 95% CI: 0.14, 0.76).
health-related quality of life
In total, 215 patients were evaluable for HRQoL assessments. 
More patients treated with talimogene laherparepvec versus GM-
CSF had improvements in each of the 11 FACT-BRM-based 
measures of HRQoL assessed (Figure 2). The TOI score 
improved in 28.0% of patients with talimogene laherparepvec 
compared with 23.4% of patients with GM-CSF (difference 
4.5%; 95% CI: -8.2%, 17.3%). The FACT-BRM total score 
improved in 37.8% of patients treated with talimogene laher-
parepvec compared with 26.9% of patients treated with GM-
CSF (difference 11.0%; 95% CI: -2.2%, 24.2%). Differences 
Table 3 Efficacy for the stage IIIB/C or IVM1a OPTiM sub-
population
T-VEC (n=163) GM-CSF (n=86)
Drr, n (%)* 41 (25.2) 1 (1.2)
95% cia 18.5, 31.8 0.0, 3.4
Best response, n (%)
complete response 27 (16.6) 0 (0.0)
Partial response 39 (23.9) 2 (2.3)
not in response 22 (13.5) 9 (10.5)
not reviewed by eacb 75 (46.0) 75 (87.2)
Orr, n (%)** 66 (40.5) 2 (2.3)
 95% cia 32.9, 48.4 0.3, 8.1
estimated Os probability, % (95% ci)
at 12 months 87.0 (80.8, 91.3) 76.8 (66.1, 84.6)
at 24 months 64.8 (56.9, 71.6) 46.2 (35.1, 56.5)
at 36 months 54.7 (46.6, 62.0) 34.3 (24.0, 44.7)
at 48 months 45.6 (35.9, 54.8) 23.4 (12.4, 36.3)
TTF per investigator 
(median), months (95% ci)
13.1 (8.3, ne) 3.3 (2.8, 4.3)
hr (95% ci) 0.27 (0.19, 0.39)
T-VEC (n=66)c GM-CSF (n=2)c
in response and censored, 
n (%)
46 (69.7) 1 (50.0)
Duration of response 
(median), monthsd
ne ne
Time to response per eac 
(median), months (95% ci)
4.0 (3.2, 5.0) 3.8 (1.9, 5.6)
T-VEC (n=67) GM-CSF (n=43)
subsequent anti-cancer therapy incidence, n (%)e
ipilimumab, vemurafenib, 
dabrafenib, trametinib 
or anti-PD1 antibody
67 (41.1) 43 (50.0)
ipilimumab 61 (37.4) 32 (37.2)
Vemurafenib 15 (9.2) 13 (15.1)
Dabrafenib 6 (3.7) 2 (2.3)
Trametinib 3 (1.8) 0 (0.0)
anti-PD1 antibody 2 (1.2) 4 (4.7)
Time to use, months – median (range)
ipilimumab, vemurafenib, 
dabrafenib, trametinib 
or anti-PD1 antibody
9.7 (2.2–52.7) 8.8 (1.4–41.4)
ipilimumab 9.7 (2.2–52.7) 9.0 (1.4–27.2)
Vemurafenib 16.2 (3.4–39.4) 13.1 (2.1–43.9)
Dabrafenib 19.4 (7.0–41.8) 7.1 (3.7–10.5)
Trametinib 18.0 (13.4–41.8) n/a
anti-PD1 antibody 19.3 (11.1–27.5) 18.7 (6.2–41.4)
Notes: aBinomial proportion with asymptotic 95% ci. bOnly patients with a best 
response per investigator of cr or Pr or receiving treatment for $9 months 
were evaluated by eac. cresponders only. dThe duration of response is defined 
as the longest individual period from entering response (PR or CR) to the first 
documented evidence of the patient no longer meeting the criteria for being in 
response or death, whichever is earlier. eData from OPTiM final analysis. *Unadjusted 
P-value ,0.0001; P-value was calculated using Fisher’s exact test and is descriptive 
for the subpopulation analyses. **P-value ,0.0001; P-value was calculated using 
Fisher’s exact test and is descriptive for the subpopulation analyses.
Abbreviations: CI, confidence interval; CR, complete response; DRR, durable 
response rate; eac, endpoint assessment committee; gM-csF, granulocyte-
macrophage colony-stimulating factor; hr, hazard ratio; n/a, not applicable; ne, 
not estimable; Orr, overall response rate; Os, overall survival; Pr, partial response; 
TTF, time to treatment failure; T-Vec, talimogene laherparepvec.
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in six of 11 measures reached statistical significance: emotional 
well-being, 22.7% (95% CI: 8.1%, 37.3%); functional well-
being, 20.8% (95% CI: 6.9%, 34.6%); social/family well-being, 
16.1% (95% CI: 1.3%, 30.8%); overall HRQoL, 19.2% (95% 
CI: 4.3%, 34.1%); pain, 18.3% (95% CI: 0.7%, 36.0%); and 
ability to work, 19.4% (95% CI: 3.5%, 35.2%).
safety
The incidence of any grade AE was similar in the two study 
arms: 98.8% versus 93.4% for talimogene laherparepvec 
and GM-CSF, respectively (Table 4). The exposure-adjusted 
AE incidence rates (per one patient-year) were 20.9 versus 
18.5 in the talimogene laherparepvec and GM-CSF arms, 
respectively. The most commonly reported AEs in either 
the talimogene laherparepvec or GM-CSF arm, respectively, 
were fatigue (50.9% versus 36.8%), chills (49.7% versus 
7.9%), pyrexia (39.9% versus 10.5%), influenza-like illness 
(33.7% versus 9.2%) and nausea (33.7% versus 21.1%; 
Table 4). Among talimogene laherparepvec-treated patients, 
the incidence of these most commonly reported AEs was 
highest during the first cycle (defined as two consecutive 
treatments with talimogene laherparepvec; fatigue 24.5%, 
chills 30.7%, pyrexia 27.6%, influenza-like illness 26.4% 
and nausea 17.8%) and decreased over time. In cycle 5, the 
incidence of fatigue, chills, pyrexia, influenza-like illness 
and nausea were 10.3%, 8.4%, 8.4%, 4.7% and 6.5%, respec-
tively. Aside from influenza-like illness (which occurred 
after a median time of 3 days), the first occurrence of the 
most common AEs coincided with the second injection of 
talimogene laherparepvec.
AEs of grade $3 and serious AEs are listed in Table 4. 
Rates of AE of grade $3 were higher in the talimogene 
laherparepvec arm versus the GM-CSF arm (32.5% versus 
23.7%, respectively; Table 4). The only serious AE occurring 
in $2% of patients was cellulitis (talimogene laherparepvec, 
n=4 [2.5%]; GM-CSF, n=0 [0.0%]). Exposure-adjusted 
serious AE incidence rates (per one patient-year) were 0.34 
versus 0.39 in the talimogene laherparepvec and GM-CSF 
arms, respectively.
The rate of discontinuation as a result of AEs was 8.6% 
and 6.6% with talimogene laherparepvec and GM-CSF, 
respectively. Respiratory, thoracic and mediastinal disorders 
(specifically, bronchial hyperreactivity, obstructive airways 
disorder, pleuritic pain and pneumonitis) most commonly 
resulted in treatment discontinuation in the talimogene 
laherparepvec arm (n=4).
Benefit–risk analyses
For every 100 patients receiving talimogene laherparepvec, an 
average of 24 additional patients achieved a durable response 
by 18 months versus GM-CSF (Figure 3A). Therefore, 
approximately four patients (100÷24) would need to be treated 
in order to experience the benefit of DRR with talimogene 
laherparepvec relative to GM-CSF by 18 months (Figure 3A). 
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Figure 2 improvement in hrQol assessed by FacT-BrM during treatment with talimogene laherparepvec and gM-csF in the stage iiiB/c or iVM1a OPTiM 
subpopulation (iTT).a
Notes: ascores from unscheduled visits were not included. a patient is considered evaluable for a domain if baseline score is not the best score, there is room for evaluable 
improvement and there is at least one post-baseline score. TOI and total improvements are defined as $5-point score increase from baseline with a $1 cycle duration. 
HRQoL, pain and work improvements are defined as $1-point score increase from baseline with a $1 cycle duration. all other subscales are based on a $2-point score 
increase from baseline with a $1 cycle duration.
Abbreviations: CI, confidence interval; FACT-BRM, Functional Assessment of Cancer Therapy-Biologic Response Modifier; GM-CSF, granulocyte-macrophage colony-
stimulating factor; hrQol, health-related quality of life; TOi, trial outcome index; T-Vec, talimogene laherparepvec.
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Over the same time period, for every 100 patients receiving 
talimogene laherparepvec, an average of five additional patients 
experienced cellulitis and two additional patients had immune-
mediated or oral herpes events versus GM-CSF (Figure 3B).
Among the talimogene laherparepvec-treated patients 
with a DRR by 18 months, ~95% did not experience any 
specified risks (Table 5). Among talimogene laherparepvec-
treated patients without durable responses by 18 months, 14% 
experienced the specified risks (Table 5).
Discussion
OPTiM was the first randomized, controlled Phase III study 
evaluating an oncolytic immunotherapy in patients with 
advanced melanoma. The study, which included both first-
line and previously treated patients (.40% received prior 
therapy), met its primary endpoint: talimogene laherparepvec 
significantly improved DRR in the unresected stage IIIB–IV 
melanoma compared with subcutaneous GM-CSF.6 A previ-
ously reported subgroup analysis of the OPTiM study sug-
gested particular benefit in patients with stage IIIB–IVM1a 
disease, with a median OS of 41.1 months for patients treated 
with talimogene laherparepvec compared with 21.5 months 
for those treated with GM-CSF (19.6-month improvement).6 
In comparison, in the OPTiM overall ITT population, a 4.4-
month improvement in median OS was observed for patients 
receiving talimogene laherparepvec versus GM-CSF.
The earlier-stage population in OPTiM is the largest 
Phase III dataset reported for patients with stage IIIB–IVM1a 
melanoma. Given the recent European Union indication 
approving talimogene laherparepvec as a treatment option 
in unresectable stage IIIB–IVM1a disease with no bone, 
brain, lung or other visceral disease, we comprehensively 
evaluated the efficacy and safety of talimogene laher-
parepvec compared with GM-CSF in this subgroup. In the 
stage IIIB–IVM1a subgroup, compared with GM-CSF, 
talimogene laherparepvec improved DRR and ORR by 24% 
and 38%, respectively. This is higher than observed in the 
OPTiM overall ITT population (14% and 21%, respectively).6 
This is also important since durable response before 1 year 
was associated with .90% decrease in the risk of death, 
and the estimated 5-year survival rate was almost 80% for 
patients with an overall response. This suggests that talimogene 
laherparepvec could delay or prevent relapses or preclude 
progression to later stage disease in this patient population. 
Indeed, a recent multivariate analysis found that talimogene 
laherparepvec-treated patients with stage IIIB–IVM1a mela-
noma had a 59% lower risk of developing visceral and bone 
metastases.16 Additionally, estimated OS probability in patients 
Table 4 summary of aes for the stage iiiB/c or iVM1a OPTiM 
subpopulation
T-VEC 
(n=163)
GM-CSF 
(n=76)
grade 1–5 aes, n (%) 161 (98.8) 71 (93.4)
grade 1–5 aes occurring with $10% frequency in $1 arm
Fatigue 83 (50.9) 28 (36.8)
chills 81 (49.7) 6 (7.9)
Pyrexia 65 (39.9) 8 (10.5)
Influenza-like illness 55 (33.7) 7 (9.2)
nausea 55 (33.7) 16 (21.1)
injection site pain 49 (30.1) 5 (6.6)
Diarrhea 35 (21.5) 7 (9.2)
Myalgia 30 (18.4) 4 (5.3)
Vomiting 30 (18.4) 7 (9.2)
Pain in extremity 29 (17.8) 6 (7.9)
Pain 28 (17.2) 9 (11.8)
arthralgia 27 (16.6) 5 (6.6)
headache 27 (16.6) 7 (9.2)
constipation 20 (12.3) 1 (1.3)
rash 20 (12.3) 4 (5.3)
Dizziness 19 (11.7) 1 (1.3)
Upper respiratory tract infection 19 (11.7) 6 (7.9)
edema peripheral 14 (8.6) 8 (10.5)
Pruritus 14 (8.6) 12 (15.8)
Decreased appetite 12 (7.4) 9 (11.8)
injection site erythema 10 (6.1) 16 (21.1)
injection site reaction 6 (3.7) 10 (13.2)
grade $3 aes, n (%) 53 (32.5) 18 (23.7)
grade $3 aes occurring in $3 patients in $1 arm
Pain in extremities 4 (2.5) 0 (0.0)
Fatigue 3 (1.8) 1 (1.3)
hypokalemia 3 (1.8) 1 (1.3)
cellulitis 3 (1.8) 0 (0.0)
Deep vein thrombosis 3 (1.8) 0 (0.0)
Dehydration 3 (1.8) 0 (0.0)
infected neoplasm 3 (1.8) 0 (0.0)
injection site pain 3 (1.8) 0 (0.0)
serious aes, n (%)
serious aes (grade 1–5) 33 (20.2) 10 (13.2)
serious aes (grade 1–5) in $2 patients
cellulitis 4 (2.5) 0 (0.0)
infected neoplasm 3 (1.8) 0 (0.0)
anemia 2 (1.2) 0 (0.0)
Disease progression 2 (1.2) 1 (1.3)
Metastasis to central nervous system 2 (1.2) 0 (0.0)
Pyrexia 2 (1.2) 0 (0.0)
rib fracture 2 (1.2) 0 (0.0)
Tumor pain 2 (1.2) 0 (0.0)
serious aes of grade $3 28 (17.2) 8 (10.5)
Treatment-related serious aes 10 (6.1) 0 (0.0)
aes leading to discontinuation of study treatment, n (%)
all 14 (8.6) 5 (6.6)
serious 8 (4.9) 3 (3.9)
non-serious 6 (3.7) 2 (2.6)
Fatal aes – on study, n (%) 1 (0.6)a 0 (0.0)
Notes: safety population included all randomized and treated subjects. subjects 
were analyzed using the treatment received. aes include all those that began 
between the first administration of study treatment and 30 days after the last 
administration of study treatment. aes were coded using MedDra version 15.1. 
anot attributed to treatment.
Abbreviations: ae, adverse event; gM-csF, granulocyte-macrophage colony-
stimulating factor; T-Vec, talimogene laherparepvec.
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with stage IIIB/C or IVM1a disease indicates that nearly twice 
as many patients treated with talimogene laherparepvec would 
be alive at 4 years, compared with GM-CSF-treated patients.
It is difficult to make comparisons between talimogene 
laherparepvec and other melanoma immunotherapies, as 
the distribution of patients across the disease stages differs 
among various other Phase III trials and total numbers of 
evaluable patients in the stage IIIB/C or IVM1a melanoma 
subpopulation are small. Specifically, the design of the tri-
als for ipilimumab, vemurafenib, nivolumab and pembroli-
zumab with different eligibility and assessment criteria,17–21 
and including fewer earlier stage metastatic patients, 
makes direct comparisons challenging. Nevertheless, the 
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Figure 3 Benefit–risk analysis. (A) Benefits by 18 months; (B) risks by 18 months for the stage iiiB/c or iVM1a OPTiM subpopulation.
Notes: immune-mediated events occurring with talimogene laherparepvec in the stage iiiB/c or iVM1a OPTiM subpopulation included glomerulonephritis/renal papillary 
necrosis (grade 2), glomerulonephritis/renal failure (grade 3), vasculitis (grade 2), pneumonitis (two episodes in one patient; grades 2 and 3) and psoriasis (two episodes in 
one patient; grades 1 and 3). Vitiligo also occurred in 12 (7%) patients; all of these events were non-serious.
Abbreviations: CI, confidence interval; GM-CSF, granulocyte-macrophage colony-stimulating factor; NNTB, number needed to treat to achieve a benefit; NNTH, number 
needed to treat to experience a harm; T-Vec, talimogene laherparepvec.
Table 5 Durable response by risk by 18 months for the stage 
iiiB/c or iVM1a OPTiM subpopulation
T-VEC GM-CSF
Patients with durable response n=41 n=1
Patients with risks,a n (%)b 2 (4.9) 0 (0.0)
Patients without risks,a n (%)b 39 (95.1) 1 (100.0)
Patients without durable response n=121 n=75
Patients with risks,a n (%)c 17 (14.0) 3 (4.0)
Patients without risks,a n (%)c 104 (86.0) 72 (96.0)
Notes: subjects who were part of both the iTT and safety population have been 
included in this summary. arisks include immune-related events, oral herpes and 
bacterial cellulitis. bPercentages were calculated using the number of patients with a 
durable response as denominator. cPercentages were calculated using the number of 
patients without a durable response as denominator.
Abbreviations: gM-csF, granulocyte-macrophage colony-stimulating factor; 
T-Vec, talimogene laherparepvec.
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numerically higher CR rate with talimogene laherparepvec 
in stage IIIB/C or IVM1a (17%) compared with other 
therapies in more advanced disease,17–21 as well as com-
pared with the overall OPTiM population, which included 
stage IVM1b/c patients (overall CR of 10.8%), highlights 
the importance of identifying and treating patients with 
melanoma early. In this regard, CR is strongly associ-
ated with long-term survival.22 Indeed, more than half of 
patients with no visceral disease treated with talimogene 
laherparepvec were alive at 3 years. Published data with 
other melanoma agents in earlier stage metastatic mela-
noma are limited.
As was seen in the overall OPTiM population, talimogene 
laherparepvec was well tolerated in patients with stage IIIB/C 
or IVM1a melanoma. The majority of AEs were of grade 1–2, 
transient and diminished over time with subsequent injec-
tions. Rates of AE of grade $3 were higher with talimogene 
laherparepvec compared with GM-CSF. However, exposure-
adjusted AE rates and serious AE rates were similar between 
the two groups (duration of treatment was .15 weeks lon-
ger with talimogene laherparepvec versus GM-CSF). The 
most frequent AE of grade $3 observed with talimogene 
laherparepvec was pain in the extremities (2.5%), and the 
remaining AEs of grade $3 occurred in ,2% of patients. 
AE-related study discontinuation was low. The NNTB and 
NNTH analyses indicated that the benefit–risk balance is in 
favor of talimogene laherparepvec. Specifically, for patients 
who responded to treatment, ~95% experienced an unquali-
fied success (benefit with no harm). In contrast, for patients 
who failed to respond, only 14% represented an unmitigated 
failure (harm with no benefit). This safety profile is favorable 
compared with other approved melanoma treatments, which 
can result in higher levels of grade $3 treatment-related 
AEs or treatment-related deaths, and with which dose inter-
ruptions and modifications may be required.17,23,24 While the 
safety profile of talimogene laherparepvec is favorable, it is 
a live, attenuated virus and appropriate precautions should be 
used during handling and administration to avoid accidental 
exposure, such as those outlined in institutional guidelines. 
In the event of accidental infection or exposure, talimogene 
laherparepvec is susceptible to antiviral agents such as 
acyclovir and famciclovir, although no cases of household 
transmission have been reported to date. Talimogene laher-
parepvec is also susceptible to common disinfectants and 
virucidal agents.
The reasons for the more pronounced efficacy with tali-
mogene laherparepvec therapy in patients with earlier-stage 
disease are not fully understood. One explanation is that hetero-
geneity in metastatic cells may increase treatment resistance, 
reducing the response to a single-agent therapeutic.25,26 Another 
explanation is that disease control with talimogene laher-
parepvec in patients with stage IIIB/C or IVM1a melanoma 
may be achieved through direct locoregional lytic effects of 
the virus, as well as immune effects, whereas responses in 
visceral lesions may be more reliant on systemic immune 
effects alone.9 In evaluation of melanoma patients treated with 
talimogene laherparepvec in a Phase II trial, MART-1-specific 
CD8+ T cells were identified in both injected and un-injected 
lesions, but the number of such cells was greater in the injected 
lesions.27 Other analyses have shown that talimogene laher-
parepvec injection may activate T cells that preferentially traf-
fic to metastases in similar anatomic sites.6,28 Thus, combining 
talimogene laherparepvec with agents that can help expand 
tumor-reactive T cells is of significant interest for enhancing 
regression of un-injected lesions. An additional explanation 
is that patients with earlier stage melanoma have a smaller 
tumor burden, and as seen with other therapies, a smaller 
tumor burden has previously been shown to be associated with 
improved clinical outcomes in patients receiving talimogene 
laherparepvec.29 Finally, it has been suggested that some 
patients with visceral disease may have had insufficient time 
to derive benefit from the talimogene laherparepvec-initiated 
systemic anti-tumor activity in the OPTiM trial.6,25,26
The limitation of this study is that the data in this explor-
atory subanalysis are inherently less robust than those of the 
OPTiM ITT population, as the study was not specifically 
designed to detect significant differences between subgroups. 
Nevertheless, the subgroup of patients with earlier-stage 
disease did represent over half of the overall population, 
and the pronounced efficacy and favorable safety profile 
indicate the utility of talimogene laherparepvec as a single 
agent in patients with earlier-stage melanoma, particularly in 
the control of locoregional disease involving skin, soft tissue 
and lymph node locations (which is often disfiguring, painful 
and psychologically disturbing).
Several unanswered questions remain from the OPTiM 
study that could help to guide the role of talimogene laher-
parepvec alongside other therapeutics in clinical practice. 
The first unanswered question is whether there are predictive 
molecular markers associated with talimogene laherparepvec 
efficacy. In this respect, biomarkers were not evaluated in 
the OPTiM study. However, studies are underway with tali-
mogene laherparepvec to evaluate immune response and to 
help identify potential predictive immune markers, such as 
intratumoral CD8+ T-cell density, peripheral blood levels 
of activated CD8+ T cells and total peripheral blood level 
of T cells (eg, ClinicalTrial.gov identifier NCT02366195). 
Preliminary data suggest that talimogene laherparepvec 
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monotherapy leads to an increase in circulating cytotoxic 
T cells (CD3+/CD8+) and an upregulation of PD-1 and TIM-3 
on these cells, providing some evidence that immune mark-
ers may ultimately be useful for evaluating efficacy with 
this therapeutic.30
A second unanswered question from the OPTiM study 
relates to whether talimogene laherparepvec should be used 
prior to checkpoint inhibitors and targeted (BRAF/MEK) 
therapies. In this regard, the recent guidelines from the National 
Comprehensive Cancer Network recommend the use of tali-
mogene laherparepvec as a primary treatment for stage III in-
transit melanoma (based on category 1 evidence) and suggest 
that checkpoint inhibitors/targeted therapies should be used 
in more advanced disease.31 Additionally, since talimogene 
laherparepvec appears to be priming the immune system, 
it may be beneficial if used prior to administration of check-
point inhibitors as a mechanism for expanding the neoantigen 
repertoire; data from clinical trials are warranted to confirm 
this clinically. Furthermore, as talimogene laherparepvec 
may augment the immune and antitumor responses, those 
patients who do not have a CR with monotherapy and can 
tolerate a greater toxicity burden may benefit from combi-
nation treatments. Indeed, the relatively low rate of grade 
3 or 4 AEs and relative lack of immune-related AEs with 
talimogene laherparepvec – and its potentially complementary 
mechanism of action with other approved melanoma agents – 
support such an investigational approach. Trials investigating 
talimogene laherparepvec in combination with other immuno-
therapies, in stage IIIB–IVM1c disease, including ipilimumab 
(NCT01740297) and pembrolizumab (NCT02263508) in 
melanoma are underway, with promising early results.30,32 
Findings to date suggest that these combinations have greater 
efficacy than either therapy alone, but with no additional safety 
concerns above those expected for each monotherapy.30,32
A third unanswered question from the OPTiM study 
relates to the sequencing of talimogene laherparepvec fol-
lowing other treatments. While response to talimogene 
laherparepvec in the OPTiM study has been reported to 
be improved in patients with treatment-naïve metastatic 
melanoma,6 line of therapy was not retained as an indepen-
dent predictor for durable response in a multivariate analysis 
considering disease stage (P=0.0763).33 Therefore, the results 
suggest that regardless of previous treatment, talimogene 
laherparepvec could be considered for patients with stage 
IIIB, IIIC or IVM1a melanoma, especially those who are 
older, given the manageable side-effect profile and positive 
benefit–risk balance. However, the OPTiM study was initi-
ated in 2009 before the availability of checkpoint inhibi-
tors and targeted (BRAF/MEK) therapies for melanoma. 
Therefore, from the OPTiM data set, it is not possible to 
ascertain the efficacy of talimogene laherparepvec following 
these now commonly used treatments.
In terms of when to consider changing treatment in 
patients receiving talimogene laherparepvec monotherapy, 
participants in the OPTiM trial were treated for a minimum 
of 6 months to allow for delayed immune-mediated anti-
tumor effects to occur. Furthermore, the current analysis 
indicates that the median time to response with talimogene 
laherparepvec monotherapy is 4 months. Additionally, 
as observed with other immunotherapies, it is important 
to note that progression prior to response can occur in a 
large number of patients (~50% with talimogene laher-
parepvec). Therefore, continued dosing in the presence of 
enlarging or new lesions in clinically stable patients could 
be considered.
Conclusion
This subgroup analysis demonstrated that treatment with 
talimogene laherparepvec, an oncolytic immunotherapy, 
improved DRR and ORR compared with GM-CSF in 
patients with earlier stage metastatic melanoma (stage IIIB, 
IIIC or IVM1a) and was well tolerated. These results sup-
port the approval for talimogene laherparepvec in Europe, 
where it is indicated for patients with regional or distantly 
metastatic (stage IIIB–IVM1a) unresectable melanoma with 
no bone, brain, lung or other visceral disease.4 Talimogene 
laherparepvec is the first treatment of its kind, and with 
European Commission and FDA approval, it represents a 
novel treatment option for patients with melanoma.
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Table S1 list of institutions involved in the design, conduct, 
analysis, and reporting of the OPTiM study
addenbrookes hospital, cambridge, UK
Baptist cancer institute, Jacksonville, Fl, Usa
Barrett cancer center, cincinnati, Oh, Usa
Boemfontein Medi-clinic, gVi Oncology, Kraaifontein, south africa
California Pacific Medical Center, San Francisco, CA, USA
cancer research UK clinical centre, st James’ University Teaching 
hospital, leeds, UK
cancer sciences Division, southampton University hospitals, 
southampton, UK
churchill hospital, Medical Oncology Unit, Oxford, UK
cleveland clinic Foundation, Taussig cancer center, cleveland, Oh, 
Usa
clinical research Unit, Jewish general hospital, Montreal, Qc, canada
columbia University Medical center, new York, nY, Usa
Duke University Medical center, Durham, nc, Usa
earle a chiles research institute, Portland, Or, Usa
emory University hospital, Winship cancer institute, atlanta, ga, Usa
gabrail cancer center, canton, Oh, Usa
greenville hospital systems, greenville, sc, Usa
gVi Oncology clinical Trials Unit, gVi Oncology, Port elizabeth, south 
africa
gVi Oncology, rondebosch Medical centre, rondebosch, cape Town, 
south africa
H Lee Moffitt Cancer Center, Tampa, FL, USA
hopelands cancer centre, Pietermaritzburg, south africa
hubert humphrey cancer center, robbinsdale, Mn, Usa
indiana University, indianapolis, in, Usa
investigative clinical research of indiana, indianapolis, in, Usa
Jon and Karen huntsman cancer, Murray, UT, Usa
Kansas city cancer center, Kansas city, MO, Usa
lakeland regional cancer center, lakeland, Fl, Usa
Leicester Royal Infirmary, Department of Oncology, Leicester, UK
Mary crowley Medical research center, Dallas, TX, Usa
Mary Potter Oncology centre, little company of Mary hospital, 
Pretoria, south africa
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MD anderson cancer ctr Orlando, Orlando, Fl, Usa
Medical University of South Carolina, Charleston, SC, USA
Midland Allison Cancer Center, Midland, TX, USA
Morristown Memorial hospital, Morristown, nY, Usa
Mount sinai ccOP, Miami Beach, Fl, Usa
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Mt sinai Medical center, Department of surgery, new York, nY, Usa
new Mexico cancer care alliance, albuquerque, nM, Usa
Onc and hem associates of southwest Virginia, salem, Va, Usa
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Palm Beach cancer center, West Palm Beach, Fl, Usa
Princess Margaret hospital, University health network, Toronto, On, 
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rhode island hospital, Providence, ri, Usa
rosebank Oncology centre, Johannesburg, south africa
roswell Park cancer institute, Buffalo, nY, Usa
royal Free hospital, academic Department of Oncology, london, UK
rush University Medical center, chicago, il, Usa
st george’s University of london, london, UK
st louis University hospital, Department of surgery, st louis, MO, Usa
st lukes cancer center, Bethlehem, Pa, Usa
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